Baricitinib

Generic Name
Baricitinib
Brand Names
Olumiant
Drug Type
Small Molecule
Chemical Formula
C16H17N7O2S
CAS Number
1187594-09-7
Unique Ingredient Identifier
ISP4442I3Y
Background

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...

Indication

In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...

Associated Conditions
Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
-

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-06-27
Last Posted Date
2024-05-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
824
Registration Number
NCT03570749
Locations
🇯🇵

Hamamatsu University School of Medicine University Hospital, Hamamatsu, Shizuoka, Japan

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Coastal Clinical Research, Inc, Mobile, Alabama, United States

and more 72 locations

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2018-06-18
Last Posted Date
2022-11-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
374
Registration Number
NCT03559270
Locations
🇺🇸

University of Utah MidValley Dematology, Murray, Utah, United States

🇺🇸

First OC Dermatology, Fountain Valley, California, United States

🇺🇸

Wallace Medical Group, Inc., Los Angeles, California, United States

and more 71 locations

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-02-15
Last Posted Date
2022-09-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
440
Registration Number
NCT03435081
Locations
🇺🇸

Care Access Research-Walnut Creek, Walnut Creek, California, United States

🇺🇸

GWU/Medical Faculty Associates, Washington, District of Columbia, United States

🇺🇸

Hamzavi Dermatology, Fort Gratiot, Michigan, United States

and more 78 locations

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

First Posted Date
2018-02-09
Last Posted Date
2024-05-14
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
463
Registration Number
NCT03428100
Locations
🇦🇹

KA Rudolfstiftung, Wien, Austria

🇦🇹

Universitätsklinik Innsbruck, Innsbruck, Tyrol, Austria

🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 100 locations

Molecular Signatures in Inflammatory Skin Disease

First Posted Date
2017-11-30
Last Posted Date
2024-12-04
Lead Sponsor
Prof. Dr. Stephan Weidinger
Target Recruit Count
300
Registration Number
NCT03358693
Locations
🇩🇪

Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-11-07
Last Posted Date
2023-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1645
Registration Number
NCT03334435
Locations
🇦🇺

Fremantle Dermatology, Perth, Western Australia, Australia

🇩🇪

Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

🇭🇺

SZTE AOK Borgyogyaszati es Allergologiai Klinika, Szeged, Csongrad, Hungary

and more 181 locations

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-11-07
Last Posted Date
2020-08-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
660
Registration Number
NCT03334396
Locations
🇲🇽

Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico

🇲🇽

RM Pharma Specialists S.A. de C.V., Distrito Federal, Mexico

🇨🇳

National Cheng Kung University Hospital, Tainan City, Taiwan

and more 89 locations

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-11-07
Last Posted Date
2020-01-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
615
Registration Number
NCT03334422
Locations
🇭🇺

Oroshaza Varosi Onkormanyzat Korhaza, Oroshaza, Hungary

🇯🇵

Nomura Dermatology Clinic, Yokohama-shi, Kanagawa, Japan

🇯🇵

Yamate Dermatological Clinic, Shinjuku, Tokyo, Japan

and more 77 locations

Baricitinib in Relapsing Giant Cell Arteritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-01-20
Last Posted Date
2022-04-08
Lead Sponsor
Matthew J Koster
Target Recruit Count
15
Registration Number
NCT03026504
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath